Oligomerix, Inc

10:45 AM - 11:00 AM (PDT), Tuesday, June 14, 2022
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease.
Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association, in order to develop medicines that are easy to administer and cost effective. Our lead compound OLOX7010 completed its pre-clinical program in 2021 and is transitioning into Ph 1a clinical development during 2Q2022
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
OLOX7010
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President
Oligomerix, Inc.